Abnormalities in the regulators of angiogenesis in patients with scleroderma

Journal of Rheumatology

Volumn 36, Issue 3, 2009, Pages 576-582

  Hummers, Laura K ^a   Hall, Amy ^b   Wigley, Fredrick M ^a   Simons, Michael ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Pulmonary arterial hypertension; Scleroderma; Vascular disease

Indexed keywords

ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; GELATINASE B; INTERSTITIAL COLLAGENASE; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; VASCULOTROPIN; ANGIOGENIC PROTEIN;

ADULT; ANGIOGENESIS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART VENTRICLE CONTRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCLERODERMA; SYSTOLIC BLOOD PRESSURE; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS;

ANGIOGENIC PROTEINS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 65649133084     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080516     Document Type: Article

References (32)

1. Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology Oxford 2005;44:587-596 (Pubitemid 41487226)
2. Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 2003;29:275-91, vi. (Pubitemid 36765121)
3. Solans R, Motta C, Sola R, et al. Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury. Arthritis Rheum 2000;43:894-900.
4. Murrell DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 1993;28:78-85. (Pubitemid 23019570)
5. Claman HN, Giorno RC, Seibold JR. Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin". Arthritis Rheum 1991;34:1495-1501
6. Freemont AJ, Hoyland J, Fielding P, Hodson N, Jayson MI. Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy. Br J Dermatol 1992;126:561-568
7. Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 1999;42:930-941 (Pubitemid 29215003)
8. Salerni R, Rodnan GP, Leon DF, Shaver JA. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977;86:394-399 (Pubitemid 8078946)
9. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996;98:785-792 (Pubitemid 26349184)
10. Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 1980;59:393-408. (Pubitemid 11241561)
11. Studer A, Hunziker T, Lutolf O, Schmidli J, Chen D, Mahler F. Quantitative nailfold capillary microscopy in cutaneous and systemic lupus erythematosus and localized and systemic scleroderma. J Am Acad Dermatol 1991;24:941-945
12. Ong YY, Nikoloutsopoulos T, Bond CP, Smith MD, Ahern MJ, Roberts-Thomson PJ. Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension. Asian Pac J Allergy Immunol 1998;16:81-86 (Pubitemid 29004827)
13. Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 1997;185:71-79 (Pubitemid 27039442)
14. Simonini G, Pignone A, Generini S, et al. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology 2000;155:1-15. (Pubitemid 32056309)
15. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006;124:175-189 (Pubitemid 43069318)
16. Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975;4:351-368
17. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-590
18. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-1576 (Pubitemid 32660630)
19. Medsger TA Jr, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-2167 (Pubitemid 29487010)
20. Mittag M, Beckheinrich P, Haustein UF. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 2001;81:294-297 (Pubitemid 32977113)
21. Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002;4:R11.
22. Choi JJ, Min DJ, Cho ML, et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003;30:1529-1533 (Pubitemid 36835451)
23. Kadono T, Kikuchi K, Kubo M, Fujimoto M, Tamaki K. Serum concentrations of basic fibroblast growth factor in collagen diseases. J Am Acad Dermatol 1996;35:392-397 (Pubitemid 26299228)
24. Jinnin M, Ihn H, Mimura Y, Asano Y, Yamane K, Tamaki K. Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 in normal and scleroderma dermal fibroblasts. J Invest Dermatol 2005;124:324-330 (Pubitemid 40175878)
25. Wu MH, Yokozeki H, Takagawa S, et al. Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma. Gene Ther 2004;11:170-180 (Pubitemid 38159689)
26. Kawaguchi Y, Harigai M, Hara M, et al. Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis. J Rheumatol 2002;29:1877-1883. (Pubitemid 34988696)
27. Kawaguchi Y, Harigai M, Fukasawa C, Hara M. Increased levels of hepatocyte growth factor in sera of patients with systemic sclerosis. J Rheumatol 1999;26:1012-1013 (Pubitemid 29195710)
28. Morishita R, Aoki M, Hashiya N, et al. Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr Gene Ther 2004;4:199-206. (Pubitemid 38842622)
29. Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 2000;43:889-893
30. Dziankowska-Bartkowiak B, Waszczykowska E, Zalewska A, Sysa-Jedrzejowska A. Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients. Mediators Inflamm 2005;2005:144-149
31. Mulligan-Kehoe MJ, Drinane MC, Mollmark J, et al. Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum 2007;56:3448-3458 (Pubitemid 47585441)
32. Mulligan-Kehoe MJ, Simons M. Current concepts in normal and defective angiogenesis: implications for systemic sclerosis. Curr Rheumatol Rep 2007;9:173-179 (Pubitemid 46932725)